Overview

Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)

Status:
Completed

Trial end date:
2004-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in reverse cholesterol transport.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Rosuvastatin Calcium